EANS-News: Sangui Bio Tech International Inc. / BioTech company Sangui strikes a positive half year balance

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Financial Figures/Balance Sheet

Witten (euro adhoc) - BioTech company Sangui strikes a positive half
year balance

Revenues grow, additional investments in marketing and sales

Witten, Germany, February 15, 2013 - While daily revenues of the
wound therapeutic Granulox grew continuously, Sangui Biotech saw its
revenues from product sales and royalties increasing quarter by
quarter since the distribution of Granulox started in April 2012. In
the first six months of its current financial year they reached
almost USD50,000. Increasingly, the wound therapeutic Granulox is the
main growth driver. Distribution rights for this product were awarded
to SastoMed GmbH by Sangui. Already, Granulox can build upon high
satisfaction with patients, excellent awareness among professionals
as well as a steady increase of order intake. In a recently published
clinical study carried out at the Charles University in Prague (Czech
Republic) a significant reduction of wound size was obtained at 97
percent of patients treated with Granulox. Documentations of
scientific radiance like this one enable SastoMed to present the
benefits of Granulox to patients and medical practitioners in an even
more convincing way. "We note that all tokens lead to the right
direction", Sangui Director Hubertus Schmelz emphasizes. "Granulox
business has gained considerable momentum now which can be derived
from the steady increase of incoming orders and revenues. As for the
quarters to come we are looking forward to additional growth in
Germany and abroad, a development which will meet our unchanged
support as shareholders of SastoMed."

Sangui BioTech International, Inc. ("SGBI") is a holding company the
shares of which are being traded on the OTCQB marketplace
(www.otcmarkets.com: SGBI) and the OTC market of Hamburg-Hannover
stock exchanges. Its purpose is to provide financing and access to
the capital markets for the enterprises of the Sangui group.
SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech
International, Inc.

Further inquiry note:
Dr. Joachim Fleing
Fon: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Sangui Bio Tech International Inc.
Alfred-Herrhausen-Strasse 44
D-58455 Witten
phone: +49(0)2302 915-200
FAX: +49(0)2302 915-191
mail: info@sangui.de
WWW: http://www.sanguibiotech.com
sector: Biotechnology
ISIN: DE0000906757
indexes:
stockmarkets: free trade: Hamburg, New York
language: English